Jennison Associates LLC increased its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 0.5% during the second quarter, according to its most recent filing with the SEC. The fund owned 973,058 shares of the medical research company’s stock after buying an additional 4,832 shares during the period. Jennison Associates LLC owned approximately 0.46% of Edwards Lifesciences Corporation worth $115,054,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the stock. Vanguard Group Inc. boosted its stake in shares of Edwards Lifesciences Corporation by 2.5% in the first quarter. Vanguard Group Inc. now owns 20,341,668 shares of the medical research company’s stock valued at $1,913,541,000 after buying an additional 505,725 shares in the last quarter. BlackRock Inc. boosted its stake in shares of Edwards Lifesciences Corporation by 2,184.9% in the first quarter. BlackRock Inc. now owns 14,003,695 shares of the medical research company’s stock valued at $1,317,326,000 after buying an additional 13,390,818 shares in the last quarter. State Street Corp boosted its stake in shares of Edwards Lifesciences Corporation by 1.7% in the first quarter. State Street Corp now owns 9,388,994 shares of the medical research company’s stock valued at $883,219,000 after buying an additional 157,844 shares in the last quarter. Alliancebernstein L.P. boosted its stake in shares of Edwards Lifesciences Corporation by 29.8% in the first quarter. Alliancebernstein L.P. now owns 6,366,425 shares of the medical research company’s stock valued at $598,890,000 after buying an additional 1,459,921 shares in the last quarter. Finally, Ameriprise Financial Inc. boosted its stake in shares of Edwards Lifesciences Corporation by 17.4% in the first quarter. Ameriprise Financial Inc. now owns 5,737,459 shares of the medical research company’s stock valued at $539,685,000 after buying an additional 850,168 shares in the last quarter. Hedge funds and other institutional investors own 84.67% of the company’s stock.

Shares of Edwards Lifesciences Corporation (NYSE:EW) opened at 113.11 on Friday. The company has a market cap of $23.88 billion, a P/E ratio of 34.31 and a beta of 0.63. The firm has a 50-day moving average price of $116.42 and a 200 day moving average price of $106.02. Edwards Lifesciences Corporation has a 12 month low of $81.12 and a 12 month high of $121.75.

Edwards Lifesciences Corporation (NYSE:EW) last announced its earnings results on Wednesday, July 26th. The medical research company reported $1.08 EPS for the quarter, topping the Zacks’ consensus estimate of $0.88 by $0.20. The firm had revenue of $842 million during the quarter, compared to analysts’ expectations of $839.16 million. Edwards Lifesciences Corporation had a return on equity of 27.17% and a net margin of 22.16%. The company’s quarterly revenue was up 10.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.76 EPS. Equities analysts predict that Edwards Lifesciences Corporation will post $3.78 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Jennison Associates LLC Has $115.05 Million Position in Edwards Lifesciences Corporation (EW)” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another domain, it was copied illegally and reposted in violation of international copyright & trademark laws. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/08/20/jennison-associates-llc-has-115-05-million-position-in-edwards-lifesciences-corporation-ew.html.

EW has been the topic of several analyst reports. Stifel Nicolaus reiterated a “buy” rating and set a $130.00 price target (up from $118.00) on shares of Edwards Lifesciences Corporation in a research report on Thursday, July 27th. Royal Bank Of Canada reiterated a “buy” rating and set a $130.00 price target on shares of Edwards Lifesciences Corporation in a research report on Friday, July 28th. Zacks Investment Research upgraded Edwards Lifesciences Corporation from a “hold” rating to a “buy” rating and set a $130.00 price target on the stock in a research report on Tuesday, July 18th. SunTrust Banks, Inc. upped their price target on Edwards Lifesciences Corporation to $14.00 and gave the company a “buy” rating in a research report on Monday, July 17th. Finally, Jefferies Group LLC upped their price target on Edwards Lifesciences Corporation from $115.00 to $132.00 and gave the company a “buy” rating in a research report on Thursday, July 27th. Five investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $120.18.

In other news, VP Donald E. Bobo, Jr. sold 5,300 shares of Edwards Lifesciences Corporation stock in a transaction that occurred on Friday, July 28th. The stock was sold at an average price of $114.68, for a total value of $607,804.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Michael A. Mussallem sold 32,900 shares of Edwards Lifesciences Corporation stock in a transaction that occurred on Wednesday, August 9th. The stock was sold at an average price of $115.99, for a total value of $3,816,071.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 149,281 shares of company stock valued at $17,331,446. Company insiders own 2.13% of the company’s stock.

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Stock Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related stocks with our FREE daily email newsletter.